Partner, King & Spalding, LLP
Mr. Ashley C. Parrish is a partner in the Washington, D.C. office of King & Spalding, and a member of the firm’s national appellate and strategic counseling practice group. He focuses his practice on appellate, administrative, and constitutional law; on the preparation of high-risk cases for eventual appeal; and on strategic, complex litigation.
Mr. Parrish frequently collaborates with the leaders of his firm’s litigation and Washington, D.C.-based regulatory practices, and, in particular, works closely with his firm’s global energy practice to serve the needs of his firm’s energy industry clients. He has handled appeals and complex litigation matters involving a wide range of subject matters in courts across the country, including significant matters before the U.S. Supreme Court, almost all of the federal courts of appeals, and a variety of state appellate courts. Mr. Parrish regularly advises clients in federal administrative law and practice, and has experience in a diverse range of substantive areas of law (including energy, bankruptcy, products liability, labor, environmental, health care, and telecommunications).
After graduating from law school, Mr. Parrish served as a law clerk to the Honorable Emilio M. Garza on the U.S. Court of Appeals for the Fifth Circuit (1998-1999).
J.D., University of Chicago Law School
B.A., Political Science, University of Washington-Seattle Campus
B.A., Economics, University of Washington-Seattle Campus
Attorney and Legal Commentator
John Shu is an attorney and legal commentator. His focus areas include constitutional law, securities & corporate law, antitrust law, administrative law, politics, and international affairs. Mr. Shu has lectured and published on a wide variety of issues.
Mr. Shu served President George H.W. Bush and President George W. Bush. He also served Judge Stanley Sporkin, U.S. District Court for the District of Columbia, who was Director of Enforcement at the U.S. Securities & Exchange Commission and General Counsel at the Central Intelligence Agency, and Judge Paul Roney, U.S. Court of Appeals for the Eleventh Circuit, who was Presiding Judge of the Foreign Intelligence Surveillance Court of Review.
Mr. Shu is a member of the National Committee on U.S. - China Relations, the Pacific Council on International Policy, and the Foreign Policy Association.
Policy Advisor, Heartland Institute
Jeff Stier is a policy advisor to the Heartland Institute.
He is widely quoted in the media and has written health policy op-eds for The Wall Street Journal, the Los Angeles Times, USA Today, The New York Post, The Washington Examiner, and Foxnews.com. The New York Times, the Associated Press, Reuters, CNN, Fox News, CNBC, MSNBC, NPR and other major outlets have interviewed and quoted Stier on a wide range of topics.
Stier has testified at state and local legislatures throughout the U.S., at FDA scientific hearings and at the Office of Management and Budget. He has also been a voice for freedom at hearings at the United Nations and in Israel’s Knesset. During more than two decades of advancing public health and defending liberty, Stier has been a speaker at CPAC, policy retreats for elected officials and medical and legal conferences.
Stier advises leading investment firms on regulatory and legal risk.
Earlier, Mr. Stier crafted health and environmental policy in the Office of the Mayor during the Giuliani administration in New York City.
Mr. Stier serves on the boards of the non-profit Jewish International Connections and Park City Jewish Collective. While earning his law degree at the Benjamin N. Cardozo School of Law, Mr. Stier served two terms as Editor-In-Chief of the Cardozo Law Forum. Jeff and his canine, BB, served as a Certified Crisis Response Strike Team with NATIONAL Crisis Response Canines, supporting survivors and first-responders.
Managing Director, Berkeley Research Group
Dan Troy is the Managing Director at Berkeley Research Group.
Prior to that, he was the Chief Business Officer, Chief Administrative Officer, and General Counsel of Valo in Boston, Massachusetts.
Prior to joining Valo, he served as the Senior Vice President & General Counsel of GlaxoSmithKline and was a member of its Corporate Executive Team. Dan joined GSK in September 2008 and was responsible for leading the company’s legal department in protecting GSK’s intellectual property; managing litigation; supporting business development transactions; and business compliance and risk management. In 2012, Dan led the integration team following the acquisition of Human Genome Sciences, which later resulted in the launch of Benlysta, the first lupus treatment in 50 years. Dan led GSK’s Contributions Committee in the US and also led the Government Affairs, Public Policy and Patient Advocacy team from 2012 until 2014.
Prior to joining GSK, he was a Partner at the Washington law firm Sidley Austin LLP, where he principally represented pharmaceutical companies and trade associations on matters related to the US Food and Drug Administration (FDA) and government regulations. Dan was formerly Chief Counsel for the FDA, where he served as a primary liaison to the White House and the US Department of Health and Human Services.
Dan has chaired the American Bar Association's Section of Administrative Law and is a member of the American Law Institute. He currently chairs the US Chamber of Commerce Litigation Center. He has also chaired the Civil Justice Reform Group, as well as the PhRMA Law Section Executive Committee. He was the 2012 CPR Corporate Leadership Award recipient and, in 2013, was named a 'Legend in the Law' at the Burton Awards.
Dan holds a B.S. in Industrial and Labor Relations from Cornell University and a J.D. from Columbia University School of Law, where he was a member of the Law Review and a Kent Scholar. After graduation from law school, he was a law clerk for the US Circuit Court of Appeals for the District of Columbia Circuit.
Partner and Co-Chair, Public Policy Group, Shook Hardy & Bacon LLP
Mark Behrens co-chairs Shook's Washington, DC-based Public Policy Practice Group and is a leading national expert on civil justice issues with over thirty years of experience. A substantial part of his practice is working to improve the civil litigation environment through state and federal legislation; in the courts through amicus curiae briefs; through legal scholarship and judicial education; and in the court of public opinion.
Mark is actively involved in civil justice reform efforts at the federal and state levels. He has testified before the U.S. Congress and most state legislatures on behalf of business and civil justice organizations. Mark also has an active amicus brief practice specializing in tort liability and civil justice issues. He has authored or co-authored over 150 amicus briefs in cases before the United States Supreme Court and federal and state appellate courts on behalf of business, civil justice, and defense lawyer organizations. In addition, Mark routinely files comments on behalf of business, civil justice, and defense lawyer organizations regarding potential changes to federal and state court rules. He chairs the International Association of Defense Counsel’s (IADC) Civil Justice Response Committee and serves on the Board of Directors of Lawyers for Civil Justice (LCJ).
Mark is a member of the American Law Institute (ALI). He received his J.D. in 1990 from Vanderbilt University Law School, where he was a member of the Vanderbilt Law Review. He received his B.A. in economics from the University of Wisconsin in 1987.
Litigation Update: Medicare Drug Pricing Negotiations
Ashley C. Parrish
Join the Federalist Society for a webinar on the ongoing legal challenges to the Biden-era...
Does President Trump Have the Authority to Pause and Modify the Medicare Drug Price Negotiation Program?
John Shu, Jeff Stier, Dan Troy
Since its inception, the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program has been...
Topics
The IRA’s Drug Price Caps Threaten Patient Health by Disincentivizing New Research
The Drug Price Negotiation Program passed—as part of the Inflation Reduction Act (IRA)—along partisan lines...
Topics
The United Nations' Misguided Approach to Healthcare Access
Intellectual property (IP) protections promote innovation and spur research and development into life-saving drugs and...
Alabama High Court Issues Landmark Drug Pricing Decision
Mark A. Behrens
Late in 2009, the Alabama Supreme Court issued one of the year’s most significant state...
Alabama AG Uses Contingency Fee Agreements to Sue Drug Manufacturers
E. Berton Spence, E Spence
Alabama Attorney General Troy King is one of numerous state attorneys general who has turned...